Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 2, 2005 - Issue 6
Submit an article Journal homepage
278
Views
26
CrossRef citations to date
0
Altmetric
Review

Advances in the delivery of treatments for Parkinson’s disease

Tom H Johnston Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, MC 11-419, Toronto, ON M5T 2S8, Canada . [email protected]
,
Susan H Fox Movement Disorder Clinic, Toronto Western Hospital, University Health Network, 399 Bathurst Street, MC 7, Toronto, ON M5T 2S8, Canada
&
Jonathan M Brotchie Atuka Ltd, 37th Floor, First Canadian Place, 100 King St W, Toronto, ON M5X 1C9, Canada. [email protected]
Pages 1059-1073 | Published online: 04 Nov 2005

Bibliography

  • LANG AE, LOZANO AM: Parkinson's disease. First of two parts. N Engl. J. Med. (1998) 339:1044–1053.
  • LANG AE, OBESO JA: Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol (2004) 3:309–316.
  • BIRKMAYER W, HORNYKIEWICZ O: [The t-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien. lain. Wochenschr. (1961) 73:787–788.
  • LANG AE, LOZANO AM: Parkinson's disease. Second of two parts. N Engl. J. Med. (1998) 339:1130–1143.
  • NUTT JG, WOODWARD WR, HAMMERSTAD JP, CARTER JH, ANDERSON JL: The 'on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl. I Med. (1984) 310:483–488.
  • NUTT JG, FELLMAN JH: Pharmacokinetics of levodopa. Neuropharmacol (1984) 7:35–49.
  • METMAN LV, KONITSIOTIS S, CHASE TN: Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov. Disord. (2000) 15:3–8.
  • BROTCHIE JM, LEE J, VENDEROVA K: Levodopa-induced dyskinesia in Parkinson's disease. Neural Transm. (2005) 112:359–391.
  • CHASE TN, KONITSIOTIS S, OH JD:Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv. Neurol (2001) 86:355–360.
  • •A succinct and authoritative account of the significance of treatment-related side effects in PD, and some of the potential mechanisms behind them.
  • BIBBIANI F, COSTANTINI LC, PATEL R, CHASE TN: Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp. Neurol (2005) 192:73–78.
  • ••Provides a clear demonstration of thepotential of using subcutaneous implants to deliver drugs in an effective way, and how this might be applied to PD.
  • CHASE TN: The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs (1998) 55\(Suppl. 1):1–9.
  • CHASE TN, ENGBER TM, MOURADIAN MM: Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology (1994) 44:S15–S18.
  • OLANOW W, SCHAPIRA AH, RASCOL O: Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends NeuroscL (2000) 23:S117–S126.
  • JENNER P: The MPTP-treated primate as a model of motor in PD: primate model of motor complications. Neurology (2003) 61:S4–S11.
  • •An excellent review, by a leader in the field, of the huge impact the MPTP model has had on drug discovery in PD.
  • PEARCE RK, HEIKKILA M, LINDEN IB, JENNER P: t-DOPA induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Neurology (2001) 156:402–409.
  • GERLACH M, DOUBLE K, ARZBERGER T, LEBLHUBER F, TATSCHNER T, RIEDERER P: Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. I Neural Transm. (2003) 110:1119–1127.
  • PEARCE RK, BANERJI T, JENNER P, MARSDEN CD: De novo administration of ropinirole and bromocriptine induces less dyskinesia than t-DOPA in the MPTP-treated marmoset. Mov. Disord. (1998) 13:234–241.
  • MARATOS EC, JACKSON MJ, PEARCE RK, JENNER P: Antiparkinsonian activity and dyskinesia risk of ropinirole and t-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov. Disord. (2001) 16:631–641.
  • RASCOL O, BROOKS DJ, KORCZYN AD, DEYN PP, CLARKE CE, LANG AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl. I Med. (2000) 342:1484–1491.
  • BEDARD PJ, PAOLO T, FALARDEAU P, BOUCHER R: Chronic treatment with t-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [31-1]spiperone binding. Brain Res. (1986) 379:294–299.
  • MARATOS EC, JACKSON MJ, PEARCE RK, CANNIZZARO C, JENNER P: Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than t-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp. Neurol (2003) 179:90–102.
  • JUNCOS JL, FABBRINI G, MOURADIAN MM, SERRATI C, KASK AM, CHASE TN: Controlled release levodopa treatment of motor fluctuations in Parkinson's disease. Neurol Neurosurg. Psychiatry (1987) 50:194–198.
  • LIEBERMAN A, GOPINATHAN G, MILLER E, NEOPHYTIDES A, BAUMANN G, CHIN L: Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. Eur. Neurol (1990) 30:75–78.
  • BLOCK G, LISS C, REINES S, IRR J, NIBBELINK D: Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur. Neurol (1997) 37:23–27.
  • RASCOL O: The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. J. Neurol (2000) 247 (Suppl. 2):I151–1157.
  • TANNER CM: Dopamine agonists in early therapy for Parkinson's disease: promise and problems. JAMA (2000) 284:1971–1973.
  • STUDY GROUP: Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. Parkinson Study Group. JAMA (2000) 284:1931–1938.
  • FOLEY P, GERLACH M, DOUBLE KL, RIEDERER P: Dopamine receptor agonists in the therapy of Parkinson's disease. J. Neural Transm. (2004) 111:1375–1446.
  • VAN CAMP G, FLAMEZ A, COSYNS B et al: Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet (2004) 363:1179–1183.
  • BLEUMINK GS, VAN MOLEN-EIJGENRAAM M, STRIJBOS JH, SANWIKARJA S, VAN PUIJENBROEK EP, STRICKER BH: Pergolide-induced pleuropulmonary fibrosis. Clin. Neuropharmacol (2002) 25:290–293.
  • FACTOR SA, MOLHO ES, FEUSTEL PJ,BROWN DL, EVANS SM: Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Neuropharmacol (2001) 24:295–299.
  • KAAKKOLA S, TERAVAINEN H, AHTILA S, RITA H, GORDIN A: Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology (1994) 44:77–80.
  • FORSBERG M, LEHTONEN M, HEIKKINEN M, SAVOLAINEN J, JARVINEN T, MANNISTO PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. I Pharmacol Exp. Ther. (2003) 304:498–506.
  • HAASIO K, LOUNATMAA K, SUKURA A: Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo. Exp. Toxicol Pathol (2002) 54:9–14.
  • OLANOW CW, KIEBURTZ K, STERN M et al: Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson's disease. Arch. Neurol (2004) 61:1563–1568.
  • SCHNEIDER E: DATATOP-STUDY: Significance of its results in the treatment of Parkinson's disease. I Neural Transm. Suppl. (1995) 46:391–397.
  • SHOULSON I: DATATOP: A decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann. Neurol (1998) 44:S160–166.
  • WARD CD: Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. Neurol Neurosurg. Psychiatry (1994) 57:217–220.
  • LEES AJ, SHAW KM, KOHOUT LJ et al: Deprenyl in Parkinson's disease. Lancet (1977) 2:791–795.
  • GOLBE LI, LIEBERMAN AN, MUENTER MD et al: Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Gila Neuropharmacol (1988) 11:45–55.
  • LEES AJ: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's disease Research Group of the United Kingdom. BE Med. 1 (1995) 311:1602–1607.
  • KOLLER W, GUARNIERI M, HUBBLE J, RABINOWICZ AL, SILVER D: An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J. Neural Transm. (2005) 112:221–230.
  • BROOKS DJ, AGID Y, EGGERT K, WIDNER H, OSTERGAARD K, HOLOPAINEN A: Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (levodopakarbidopaientacapone) and levodopaiddci given in combination with comtess®/comtan® (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur. Neurol (2005) 53:197–202.
  • SMITH LA, JACKSON MJ, AL-BARGHOUTHY G et al: Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord. (2005) 20:306–314.
  • ••A rigorous and scientifically credible studyIn the highly predictive MPTP-lesioned primate model of PD that provides a clear rationale for approaches combining L-DOPA and catechol- 0-methyltransferase Inhibitors.
  • ADLER CH, SETHI KD, HAUSER RA et al: Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology (1997) 49:393–399.
  • BROOKS DJ, ABBOTT RJ, LEES AJ et al: A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Neuropharmacol (1998) 21:101–107.
  • WHONE AL, WATTS RL, STOESSL AJ et al: Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol (2003) 54:93–101.
  • RASCOL O, LEES AJ, SENARD JM, PIRTOSEK Z, MONTASTRUC JL, FUELL D: Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin. Neuropharmacol (1996) 19:234–245.
  • IM JH, HA JH, CHO IS, LEE MC: Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. J. Neurol (2003) 250:90–96.
  • GUPTHA SH, PROMNITZ AD: Pleural effusion and thickening due to cabergoline use in a patient with Parkinson's disease. Eur. J. Intern. Med. (2005) 16:129–131.
  • TOWNSEND M, MACIVER DH: Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease. Heart (2004) 90:e47.
  • HORVATH J, FROSS RD, KLEINER-FISMAN G et al: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. (2004) 19:656–662.
  • CLARKE A, BREWER F, JOHNSON ES et al: A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. I Neural Transm. (2003) 110:1241–1255.
  • CLARKE A, JOHNSON ES, MALLARD N et al: A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. I Neural Transm. (2003) 110:1257–1271.
  • ••Clinical demonstration of the efficacy ofthe new Zydis wafer formulation of selegiline.
  • FINBERG JP, LAMENSDORF I, WEINSTOCK M, SCHWARTZ M, YOUDIM MB: Pharmacology of rasagiline (1\1-propargy1-1R-aminoindan). Adv. Neurol (1999) 80:495–499.
  • OLANOW CW, STOCCHI F: COMT inhibitors in Parkinson's disease: can they prevent anclior reverse levodopa-induced motor complications? Neurology (2004) 62:S72–S81.
  • MANDEL S, WEINREB O, AMIT T, YOUDIM MB: Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev (2005) 48:379–387.
  • HAUSER RA, LEW M, HURTIG H, ONDO W, WOJCIESZEK J: Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Mov. Disord. (2005) 20:P251.
  • KURLAN R, RUBIN AJ, MILLER C, RIVERA-CALIMLIM L, CLARKE A, SHOULSON I: Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann. Neurol (1986) 20:262–265.
  • KURTH MC, TETRUD JW, TANNER CM et al.: Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopaicarbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology (1993) 43:1698–1703.
  • NYHOLM D, REMAHL AT, DIZDAR N et al.: Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson's disease. Neurology (2005) 64: 216–223.
  • •This study, although not double blind, represents the most useful evaluation to date of the novel duodenal f-DOPA infusion approach.
  • NILSSON D, NYHOLM D, AQUILONIUS SM: Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta. Neurol Scand. (2001) 104:343–348.
  • CHAUDHURI KR, CRITCHLEY P, ABBOTT RJ, PYE IF, MILLAC PA: Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet (1988) 2:1260.
  • FRANKEL JP, LEES AJ, KEMPSTER PA, STERN GM: Subcutaneous apomorphine in the treatment of Parkinson's disease. Neurol Neuracurg. Psychiatry (1990) 53:96–101.
  • DEWEY RB HUTTON JT, LEWITT PA, FACTOR SA: A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch. Neurol (2001) 58:1385–1392.
  • MANSON AJ, HANAGASI H, TURNER K et al: Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain (2001) 124:331–340.
  • ROSA AE, EPIFANIO A, ANTONINI A et al.: Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Neurol Sci. (2003) 24:174–175.
  • MORGANTE L, BASILE G, EPIFANIO A et al.: Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch. amnia Ceriatr. Suppl (2004):291–296.
  • KATZENSCHLAGER R, HUGHES A, EVANS A et al: Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. (2005) 20:151–157.
  • •Highlights an often overlooked use for continuous dopamine receptor stimulation, to reverse the process of priming for dyskinesia.
  • KOLLER W, STACY M: Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology (2004) 62:S22–S26.
  • DEWEY RB Jr. MARAGANORE DM, AHLSKOG JE, MATSUMOTO JY: Intranasal apomorphine rescue therapy for parkinsonian 'off' periods. Clin. Neuropharmacol (1996) 19:193–201.
  • DEWEY RB MARAGANORE DM, AHLSKOG JE, MATSUMOTO JY: A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Mov. Disord. (1998) 13:782–787.
  • HUGHES AJ, WEBSTER R, BOVINGDON M, LEES AJ, STERN GM: Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. Clin. Neuropharmacol (1991) 14:556–561.
  • LEES AJ, MONTASTRUC JL, TURJANSKI N et al: Sublingual apomorphine and Parkinson's disease. Neurol Neurosurg. Psychiatry (1989) 52:1440.
  • MONTASTRUC JL, RASCOL O, SENARD JM, HOUIN G, RASCOL A: Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?' Neural Transm. Suppl (1995) 45:157–161.
  • ONDO W, HUNTER C, ALMAGUER M, JANKOVIC J: A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov. Disord. (1999) 14:664–668.
  • VAN LAAR T, NEEF C, DANHOF M, ROON KI, ROOS RA: A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. Mov. Disord. (1996) 11:633–638.
  • VAN LAAR T, JANSEN EN, NEEF C, DANHOF M, ROOS RA: Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov. Disord. (1995) 10:433–439.
  • HUGHES AJ, BISHOP S, LEES AJ, STERN GM, WEBSTER R, BOVINGDON M: Rectal apomorphine in Parkinson's disease. Lancet (1991) 337:118.
  • STUDY GROUP: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol (2003) 60:1721–1728.
  • METMAN LV, GILLESPIE M, FARMER C et al: Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin. Neuropharmacol (2001) 24:163–169.
  • SCHACHTER M, BLACKSTOCK J, DICK JP, GEORGE RJ, MARSDEN CD, PARKES JD: Lisuride in Parkinson's disease. Lancet (1979) 2: 1129.
  • VAAMONDE J, LUQUIN MR, OBESO JA: Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain (1991) 114 (Pt 1B):601–617.
  • BARONTI F, MOURADIAN MM, DAVIS TL et al.: Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann. Neurol (1992) 32:776–781.
  • CRITCHLEY PH, PEREZ F, QUINN NP, PARKES JD, MARSDEN CD: Continuous subcutaneous lisuride infusions in Parkinson's disease. I Neural Transm. Suppl (1988) 27:55–60.
  • HEINZ A, SUCHY I, KLEWIN I, KUHN KLOTZ P, PRZUNTEK H: Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease. I Neural Transm. Park. Dis. Dement. Sect. (1992) 4:291–301.
  • WOITALLA D, MULLER T, BENZ S, HOROWSKI R, PRZUNTEK H: Transdermal lisuride delivery in the treatment of Parkinson's disease. I Neural Transm. Suppl (2004) 68:89–95.
  • DURING MJ, FREESE A, DEUTCH AY et al: Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes. Exp. Neurol (1992) 115:193–199.
  • STEFANO A, CARAFA M, SOZIO P et al.: Evaluation of rat striatal L-DOPA and DA concentration after intraperitoneal administration of L-DOPA prodrugs in liposomal formulations. J. Control. Release (2004) 99:293–300.
  • BARTUS RT, EMERICH D, SNODGRASS-BELT P et al: A pulmonary formulation of t-DOPA enhances its effectiveness in a rat model of Parkinson's disease. J. Pharmacol Exp. Ther. (2004) 310:828–835.
  • ••A predinical demonstration of thepotential of the novel AIR technology.
  • FREED CR, GREENE PE, BREEZE RE et al.: Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl. J. Med. (2001) 344:710–719.
  • HAGELL P, PICCINI P, BJORKLUND A et al.: Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. (2002) 5:627–628.
  • WATTS RL, RAISER CD, STOVER NP et al.: Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease. J. Neural Transm. Suppl (2003):215–227.
  • SUBRAMANIAN T, MARCHIONINI D, POTTER EM, CORNFELDT ML: Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant. (2002) 11:207–214.
  • BAKAY RA, RAISER CD, STOVER NP et al.: Implantation of Spheramine in advanced Parkinson's disease (PD). Front. Biosci. (2004) 9:592–602.
  • •Initial findings of the ongoing clinical studies evaluating the safety and efficacy of the microcarrier-retinal pigment cell-based technology in delivering t-DOPA-producing cells to the brain.
  • PUSKOVIC V, WOLFE D, GOSS J et al: Biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol. Ther. (2004) 10:67–75.
  • CUNNINGHAM LA, SU C: Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp. Neurol (2002) 174:230–242.
  • GEORGIEVSKA B, KIRIK D, ROSENBLAD C, LUNDBERG C, BJORKLUND A: Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport (2002) 13:75–82.
  • THI NA, SAILLOUR P, FERRERO L,DEDIEU JF, MALLET J, PAUNIO T: Delivery of GDNF by an El, E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Ther. (2004) 11:746–756.
  • WANG J, ZHANG PC, MAO HQ, LEONG KW: Enhanced gene expression in mouse muscle by sustained release of plasmid DNA using PPE-EA as a carrier. Gene Ther. (2002) 9:1254–1261.
  • SUWELACK D, HURTADO-LORENZO A, MILLAN E et al: Neuronal expression of the transcription factor Glil using the Talphal alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease. Gene Ther. (2004) 11:1742–1752.
  • KLEIN RL, LEWIS MH, MUZYCZKA N, MEYER EM: Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res. (1999) 847:314–320.
  • CARLSSON T, WINKLER C, BURGER C et al: Reversal of dyskinesias in an animal model of Parkinson's disease by continuous t-DOPA delivery using rAAV vectors. Bran] (2005) 128:559–569.
  • LUO J, KAPLITT MG, FITZSIMONS HL et al.: Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science (2002) 298:425–429.
  • ZHANG Y, SCHLACHETZKI F, ZHANG YF, BOADO RJ, PARDRIDGE WM: Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene Ther. (2004) 15:339–350.
  • ZHANG Y, CALON F, ZHU C, BOADO RJ, PARDRIDGE WM: Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. (2003) 14:1–12.
  • BRACCO F, BATTAGLIA A, CHOUZA C et al: The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs (2004) 18:733–746.
  • NYHOLM D, ASKMARK H, GOMES-TROLIN C et al: Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Chi'. Neuropharmacol (2003) 26:156–163.
  • MOURADIAN MM: Should levodopa be infused into the duodenum? Neurology (2005) 64:182–183.
  • Parcopa: a rapidly dissolving formulation of carbidopa/levodopa. Med. Lett. Drugs Ther. (2005) 47:12.
  • WATERS CH, SETHI KD, HAUSER RA, MOLHO E, BERTONI JM: Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord. (2004) 19:426–432.
  • MAHMOOD I: Selegiline transdermal system Somerset. Curr. Opin. Investig. Drugs (2002) 3:1230–1233.
  • PFEIFFER RF: Potential of transdermal drug delivery in Parkinson's disease. Drugs Aging (2002) 19:561–570.
  • HONEYWELL-NGUYEN PL, ARENJA S, BOUWSTRA JA: Skin penetration and mechanisms of action in the delivery of the D2-agonist rotigotine from surfactant-based elastic vesicle formulations. Pharm. Res. (2003) 20:1619–1625.

Websites

  • http://www.parcopa.com/ 6-27-041aunchRelease.html Schwarz Pharma announces launch of Parcopa orally dissolving tablets for Parkinson's disease (2004).
  • hdp://www.rochecanada.com Roche Canada website.
  • http://www.merck.com Merck website.
  • http://www.requip.com/hp-rel.html Information about REQUIP for patients and caregivers.
  • http://www.mirapex.com/hcp/tools/ references.asp Mirapex reference site.
  • http://www.parkinson.org/site/ pp.asp?c=9dJFJLPwB&b=108396 National Parkinson's Foundation website.
  • hdp://www.somersetpharm.com/products/ Eldepryl information site.
  • http://www.pharma.us.novartis.com Novartis Pharmaceuticals USA website.
  • http://www.parcopa.com Parcopa Tm information site.
  • hdp://www.alkermes.com/products/ inhaled.html Alkermes' AIR® technology information site.
  • http://www.valeant.com/ researchAndDevelopment/developmentjspf Valeant Pharmaceuticals International Research and Development site.
  • http://www.apokyn.com Apokyn website.
  • http://www.apomorphine.co.uld intermittent/pen_spc/ apg-p_spc_v2_10-2002a.html Apomorphine information site.
  • http://www.nastech.comThastech/nasal Nastech's nasal drug delivery information site.
  • http://www.cardinal.com/content/news/ 022599_74350.asp Cardinal Health news report.
  • http://www.aderis.com/products/ rotigotine.htm Aderis Pharmaceuticals: products in development.
  • http://www.skyepharma.com/ upcoming_requip.html Upcoming products from SkyePharma.
  • http://www.prestwickpharma.com Prestwisck Pharmaceuticals website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.